multiple cancers
Oncology · 2020–2022
No submission for this condition has carried consumer input, including the 2 made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| pembrolizumab Addition of 400 mg every six weeks dosing regimen for multiple oncology indications including urothelial cancer, colorectal cancer, primary mediastinal B-cell… | Jul 2022 | Recommended with restriction | none received |
| bevacizumab Biosimilar to Avastin for metastatic colorectal cancer, advanced/metastatic/recurrent non-squamous NSCLC, relapsed or recurrent glioblastoma, epithelial… | Jul 2020 | Recommended | none received |
What the PBS pays
$789M in government benefit over 2024–25, across 165,461 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| pembrolizumab | $739.6M |
| bevacizumab | $49.4M |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| bleomycinBLEO 15K bleomycin sulfate 15000 IU powder for injection vial | 1994 | 5 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.